Evidence map›Paper›PMID 41553537›Full record

ArticleCancer chemotherapy and pharmacology2026

Analysis of intercellular lipids in the stratum corneum of patients with capecitabine-induced hand-foot syndrome: comparison with the stratum corneum of healthy individuals.

Tomonobu Uchino, Michiaki Nakajo, Ichiro Hatta, Ikumi Suzuki, Mayuko Okada, Rikuto Terada, Yasunori Miyazaki, Misa Osawa, Keisei Taku, Tasuku Yokoyama and 2 more

Abstract readComparative Study
PubMed Publisher
In one paragraph

Article in Cancer chemotherapy and pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Tomonobu UchinoDepartment of Clinical Pharmaceutics, Graduate School of Pharmaceutical Sciences, University of Shizuoka, 52-1 Yada, Suruga-ku, Shizuoka, 422-8526, Japan. uchinot@u-shizuoka-ken.ac.jp.ORCID http://orcid.org/0000-0001-8667-9365
Michiaki NakajoDepartment of Clinical Pharmaceutics, Graduate School of Pharmaceutical Sciences, University of Shizuoka, 52-1 Yada, Suruga-ku, Shizuoka, 422-8526, Japan.
Ichiro HattaDepartment of Research, Nagoya Industrial Science Research Institute, 1-13 Yotsuyadori, Chikusa-ku, Nagoya, 464-0819, Japan.
Ikumi SuzukiDepartment of Clinical Pharmaceutics, School of Pharmaceutical Sciences, University of Shizuoka, 52-1 Yada, Suruga-ku, Shizuoka, 422-8526, Japan.
Mayuko OkadaDepartment of Clinical Pharmaceutics, School of Pharmaceutical Sciences, University of Shizuoka, 52-1 Yada, Suruga-ku, Shizuoka, 422-8526, Japan.
Rikuto TeradaDepartment of Clinical Pharmaceutics, School of Pharmaceutical Sciences, University of Shizuoka, 52-1 Yada, Suruga-ku, Shizuoka, 422-8526, Japan.
Yasunori MiyazakiDepartment of Clinical Pharmaceutics, Graduate School of Pharmaceutical Sciences, University of Shizuoka, 52-1 Yada, Suruga-ku, Shizuoka, 422-8526, Japan.
Misa OsawaDepartment of Pharmacy, Shizuoka General Hospital, 4-27-1 Kita-Ando, Aoi-ku, Shizuoka, 420-8527, Japan.
Keisei TakuDepartment of Oncology, Shizuoka General Hospital, 4-27-1 Kita-Ando, Aoi-ku, Shizuoka, 420-8527, Japan.
Tasuku YokoyamaDepartment of Clinical Pharmaceutics, Graduate School of Pharmaceutical Sciences, University of Shizuoka, 52-1 Yada, Suruga-ku, Shizuoka, 422-8526, Japan.
Daiki TsujiDepartment of Clinical Pharmaceutics, Graduate School of Pharmaceutical Sciences, University of Shizuoka, 52-1 Yada, Suruga-ku, Shizuoka, 422-8526, Japan.
Yoshiyuki KagawaDepartment of Clinical Pharmaceutics, Graduate School of Pharmaceutical Sciences, University of Shizuoka, 52-1 Yada, Suruga-ku, Shizuoka, 422-8526, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeCapecitabine (CAP) side effect, a prodrug of 5-fluorouracil (5-FU), is hand-foot syndrome (HFS), a localized skin disorder of the hands and feet that is believed to induce a decrease in skin barrier function. Stratum corneum (SC) lipids play an important role in skin barrier function; therefore, this study compared the SC lipid structure and composition of healthy participants with those of patients with CAP-induced HFS.

methodsForty patients receiving a combination regimen of CAP and oxaliplatin as adjuvant chemotherapy for colorectal cancer were enrolled. All patients received 1,000 mg/m

resultsIn healthy SC (HSC), lipids formed two lamellar phases. Hexagonal and orthorhombic hydrocarbon chain packing was observed in lateral lipid organization. However, in CSC, these structures have almost disappeared. UPLC-MS/MS analysis revealed that the composition of CER and FFA differed between CSC and HSC, and that the carbon chain length of SC lipid components in CSCs was reduced compared to that in HSCs. 5-FU was detected in CSCs at 3.4 ± 1.4 ng/mg.

conclusionCAP induces changes in SC lipid structure due to changes in SC lipid composition and a decrease in carbon chain length in CSCs. CAP-induced HFS is associated with 5-FU accumulation in SC.

Indexed as

CapecitabineHand-Foot SyndromeLipidsAdultAgedAntimetabolites, AntineoplasticAntineoplastic Combined Chemotherapy ProtocolsColorectal NeoplasmsFemaleHumansMaleMiddle AgedOxaliplatinTandem Mass SpectrometryAntimetabolites, AntineoplasticCapecitabineLipidsOxaliplatinCapecitabineCeramideHand-foot syndromeLamellar structureLateral structureStratum corneum

Identifiers

PMID41553537

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.